Slide 1: Q3/2021 Results and Corporate Update
© Immunic ct Update 4 Results-and
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements “This presentation contains “forward-looking statements” hat invoNe substantia sks and uncertainties for purposes ofthe safe harbor within the meaning of Section 27A ofthe Sects Act 0933, asamended, and Section 21 of the Secures Exchange Act of 19
Slide 3: Agenda: Q3/2021 Financial Results and Corporate Update
) Agenda: Q3/2021 Financial Results and Corporate Update Third Quarter 2021 and Subsequent Highlights Q&A Session Financial and Operating Results Summary and Highlights Anticipated Clinical Milestones 3. | ©lmmunig inc. | Nov/o4/2022 © Immunic
Slide 4: Development Pipeline: Multiple Milestones Expected in 2022
Development Pipeline: Multiple Milestones Expected in 2022 Program _| Target Preclinical Phasel | __ Phase 2 Phase 3 Key 2021/22 Milestones Phase 3 RRMS: first-patier ‘expected in 4/2021 (muse BROCE Phase 2 UC: top-line data expected in Q2/2022 Phase 1 healthy volunteers: unblinded SAD/MAD safety da
Slide 5: Slide 5
Slide 6: July: Hosted a Virtual R&D Day on IMU-935
" \ July: Hosted a Virtual R&D Day to Provide an Update on the Preclinical and Clinical Development of IMU-935 = IMU-935 has been observed to be a potent RORyt inhibitor with an IC, on IL-17A and IL-17F inhibition of <5 nM = IMU-935 demonstrated a selective effect of inhibition of Th17 differentiati
Slide 7: July: Completed a USD 45.0 Million Underwritten Public Offering
July: Completed a USD 45.0 Million Underwritten Public Offering of Common Stock, Extending Cash Runway Into 2023 Offering Summary Gross / Net Proceeds Use of Proceeds Launch / Pricing / Closing Date Sole Bookrunner Co-Managers 7 | ©lmmunic, Inc. | Nov/o4/2021 = Underwritten public offering of 4,500,
Slide 8: September: Signed an In-License Agreement With the University Medical Center Göttingen
September: Signed an In-License Agreement With the University Medical Center Gottingen, Germany Preclinical research has shown that certain DHODH inhibitors, including ai IMU-838, strongly synergize with selected nucleoside analogues to inhibit SARS-CoV-2 replication in vitro = Executed an in-licens
Slide 9: September: Enrolled the First Patient in the Phase 2 CALLIPER Trial
September: Enrolled the First Patient in the Phase 2 CALLIPER Trial of IMU-838 in Patients with Progressive Multiple Sclerosis Ongoing Multicenter, Randomized, Double- Blind, Placebo-Controlled Phase 2 Trial* * Approximately 450 patients in more than 70 sites in North Coordinating Investigator Ameri
Slide 10: October: Appointed Patrick Walsh as Chief Business Officer
October: Appointed Patrick Walsh to the Newly Created Role of Chief Business Officer 10 | ©Immunic, Inc. | Nov/o4/2021 Mr. Walsh is responsible for business development, including strategic partnering opportunities, and has become part of the executive management team of Immunic. Mr. Walsh joined Im
Slide 11: October: Dosed the First Psoriasis Patient in Phase 1 Trial of IMU-935
part A Evaluation of single ascending doses (SAD) Healthy volunteers randomized to receive single dose of IMU-935 or placebo Dose escalation completed: 100, 200, 300 and 400 mg of IMU-935 79 subjects enrolled (still blinded) IMU-935 was well-tolerated and showed dose-linear PK ‘re pharmacovnetes 41
Slide 12: October: Randomized the Last Patient in the Phase 2 CALDOSE-1 Trial
October: Randomized the Last Patient in the Phase 2 CALDOSE-1 Trial of IMU-838 in Patients With Ulcerative Colitis* Induction Phase Maintenance Phase Placebo (n=60) + Placebo (n=60) 10 mg IMU-838 QD Optional mg IMU- Seal ——————— Patients with open-label symptomatic extension remission > 10mg IMU-838
Slide 13: Slide 13
Slide 14: Condensed Consolidated Statements of Operations
Condensed Consolidated Statements of Operations (In thousands, except share and per share amounts, unaudited) Three Months Nine Months Ended September 30, Ended September 30, 2021 2020. 2021 2020 (Operating expenses: Research and development i$ 15,480. S 11,040 iS 42,737 iS 27,461 General and admini
Slide 15: Slide 15
Slide 16: IMU-838 in Relapsing Multiple Sclerosis
IMU-838 in Relapsing Multiple Sclerosis ; 5 The twin, multicenter, randomized, double-blind, phase 3 ENSURE-1 and ENSURE-2 trials of 30 mg daily IMU- 838 or placebo will run concurrently. ~ & . / Dosing of the first patient is expected in Q4/2021. © Immunic
Slide 17: IMU-838 in Ulcerative Colitis
IMU-838 in Ulcerative Colitis Top-line data of the induction phase of the phase 2 CALDOSE-1 trial of IMU-838 in patients with moderate- to-severe UC is expected to be available in Q2/2022. 47 | © immuric, Inc © Immunic
Slide 18: IMU-935 Phase 1 Program in Healthy Volunteers and Psoriasis
IMU-935 Phase 1 Program in Healthy Volunteers and Psoriasis The experimental phase of the MAD part has recently been completed. Unblinded safety, pharmacodynamic and pharmacokinetic data from the SAD and MAD parts in healthy volunteers is expected to be available in Q4/2021. Initial human data from
Slide 19: IMU-935 Phase 1 Trial in CRPC
IMU-935 Phase 1 Trial in CRPC ve 4 Principal Investigator Johann Sebastian de Bono, M.D., Ph.D. Regius Professor of Cancer Research and Professor in Experimental Cancer Medicine The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust London, United Kingdom An open-label phase 1 d
Slide 20: IMU-856 Phase 1 Trial Update
The SAD part of the ongoing phase 1 trial of IMU- 856 has been completed. Based on the favorable data available so far, t s Committee in Australia has agreed to proceed to the MAD part and the first cohort is currently being dosed Unblinded safety data from the SAD and MAD parts in healthy volunteer
Slide 21: Slide 21
Slide 22: Slide 22
Slide 23: Summary and Highlights
Summary and Highlights vanced and well-balanced pipeline: Three differentiated products in various phases of clinical development Excellent phase 2 data in RRMS: IMU-838 met all statistical endpoints and underlined favorable safety and tolerability profile PE 3 prog n RRMS: Expected to start in Q4/2
Slide 24: Thank You!
Thank You! Head of IR & Communications Phone: +49-89-2080477-09 Email: ir@imux.com Web: www.imux.com 24 | ©tmmunic, Inc. | Nov/04/2021 Immunic, Ine. 1200 Avenue of the Americas Immunic AG New York City, NY 10036 Grafelfing (Munich) usA Germany = Immunic Research GmbH == A Weinberg campus Halle (Saal